We are live on ! Find out more
PRVB

Provention Bio, Inc. Common Stock
PRVB

Delisted

PRVB was delisted on the 26th of April, 2023.

Back to rankings

113 hedge funds and large institutions have $177M invested in Provention Bio, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 26 increasing their positions, 37 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

396% more call options, than puts

Call options by funds: $8M | Put options by funds: $1.61M

33% more capital invested

Capital invested by funds: $133M → $177M (+$43.9M)

11% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 19

1% more funds holding

Funds holding: 112 → 113 (+1)

30% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 37

Holders
113
Holders Change
+1
Holders Change %
+0.89%
% of All Funds
1.78%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
21
Increased
26
Reduced
37
Closed
19
Calls
$8M
Puts
$1.61M
Net Calls
+$6.39M
Net Calls Change
+$3.52M

Top Buyers

Rank Fund Capital Flow
1
VA
VR Adviser
New York
+$6.69M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$4.24M
3
Invesco
Invesco
Georgia
+$1.23M
4
SC
Sessa Capital
New York
+$625K
5
Morgan Stanley
Morgan Stanley
New York
+$533K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$3.07M
2
Verition Fund Management
Verition Fund Management
Connecticut
-$2.43M
3
PA
Perceptive Advisors
New York
-$938K
4
Truist Financial
Truist Financial
North Carolina
-$843K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$828K

PRVB Hedge Fund Activity: Q1 2022 in Review

113 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q1 2022, worth a combined $177M — up 33% from $133M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new PRVB positions and 19 closed out — a net gain of 2 holders — while 26 added to existing stakes and 37 trimmed.

The largest buyer was VR Adviser, opening a new position worth an estimated $6.69M. The largest seller was Millennium Management, exiting entirely with an estimated $3.07M sold.

  • 113 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q1 2022, up from 112 in Q4 2021.
  • Funds reported $177M of Provention Bio, Inc. Common Stock stock for Q1 2022, up 33% quarter-over-quarter.
  • 21 funds opened new Provention Bio, Inc. Common Stock positions in Q1 2022 and 19 closed out, a net change of +2 holders.
  • The largest Provention Bio, Inc. Common Stock buyer in Q1 2022 was VR Adviser, an estimated $6.69M added.
  • The largest Provention Bio, Inc. Common Stock seller in Q1 2022 was Millennium Management, an estimated $3.07M sold.

Based on aggregated 13F filings for Q1 2022.